Skip to content
Research Article Open access CC BY 4.0

An Appraisal of the Drug Discovery Process in Neuroscience

M. O. Nwokike, S. I. Ghasi, M. N. Ezenwaeze, A. O. Ogbonna, A. C. Ezinwa, C. C. Offor

International Neuropsychiatric Disease Journal · pp. 5–15 · Published 6 May 2022

10.9734/indj/2022/v17i230195

Abstract

The scientific study of the nervous system is a major area for disease and consequently disease management. The use of drugs to treat neurological disease is the backbone of this sphere of therapy. This review will concentrate of the history, process, constraints and novelty of drug discovery for these disorders. It will enhance understanding and contribute to an improved efficiency of the drug development process. The history of drug discovery in neuroscience follows the pattern of other discoveries in civilisation. Solutions obtained by steeping or soaking natural substances comprised the only source of medicines until data-based processes were developed to; remove impurities from, increase the concentration of, and separate active substances from these extracts. In most cases, the development of a new medicinal drug starts when scientists learn of a target that is involved in a natural process thought to be impaired in function for patients with sicknesses such as Alzheimer's disease. Better medicines that are improvements on current medications are further found to have greater value as they offer benefits over existing ones for disease treatment, prevention or alleviation in terms of potency, safety, tolerability, or convenience. Regulatory agencies are set up to ensure conformity to steps and standards for improved safety and efficacy. In accordance with this, neurological drugs have less success rates and take more time to acquire, than do other drug classes.

Discovery preclinical clinical pharmacovigilance neuroscience

References (27)

  1. 1 A new approach to practical acute toxicity testing [DOI]
  2. 2 Raise standards for preclinical cancer research [DOI]
  3. 3 Drug Discovery: A Historical Perspective [DOI]
  4. 4 Alzheimer’s disease drug-development pipeline: few candidates, frequent failures [DOI]
  5. 5 Tests to assess motor phenotype in mice: a user's guide [DOI]
  6. 6 Drug discovery and development: Role of basic biological research [DOI]
  7. 7 Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation [DOI]
  8. 8 The Metabolic Effects of Antipsychotic Medications [DOI]
  9. 9 Nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood–Brain Barrier: Challenges and Possibilities [DOI]
  10. 10 Animal Experiments in Biomedical Research: A Historical Perspective [DOI]
  11. 11 Animal use in pharmacology education and research: The changing scenario [DOI]
  12. 12 Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases [DOI]
  13. 13 Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles [DOI]
  14. 14 Drug Discovery: A History [DOI]
  15. 15 Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics [DOI]
  16. 16 Stereotypy in schizophrenia [DOI]
  17. 17 Microdosing: A Critical Assessment of Human Data [DOI]
  18. 18 Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression [DOI]
  19. 19 Strategies to Address Challenges in Neuroscience Drug Discovery and Development [DOI]
  20. 20 Akathisia: overlooked at a cost [DOI]
  21. 21 Drugs: From discovery to approval [DOI]
  22. 22 Approaches for The Rapid Identification of Drug Metabolites in Early Clinical Studies [DOI]
  23. 23 Delivering Drugs Into the Brain: Barriers and Possibilities [DOI]
  24. 24 Rat–Mouse and Rat–Human Comparative Maps Based on Gene Homology and High-Resolution Zoo-FISH [DOI]
  25. 25 Involvement of NMDA Receptors in Thiopental-Induced Loss of Righting Reflex, Antinociception and Anticonvulsion Effects in Mice [DOI]
  26. 26 Rising Research and Development Costs for New Drugs in a Cost Containment Environment [DOI]
  27. 27 Cold Spring Harbor Perspectives in Biology [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

23

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.